CTHRepealedLegislation
National Health Act 1953 - Arrangements made under subparagraph 100(1)(b)(i) - Chemotherapy Pharmaceuticals Access Program (No. PB 37 of 2006)
24Claims for payment for the supply of chemotherapy pharmaceuticals under these Arrangements
Start here
Get a plain-English read of 24
Turn the raw legal text into a practical explanation grounded in National Health Act 1953 - Arrangements made under subparagraph 100(1)(b)(i) - Chemotherapy Pharmaceuticals Access Program (No. PB 37 of 2006).
Claims for payment for the supply of chemotherapy pharmaceuticals under these Arrangements
-
The approved hospital authority must prepare an electronic pharmacy record in respect of each medication chart in respect of which a chemotherapy pharmaceutical has been supplied to a patient of the hospital, and must retain that electronic pharmacy record for not less than one year after the day on which the chemotherapy pharmaceutical was supplied.
-
The electronic pharmacy record referred to in paragraph 24 must contain all information required to be included in a prescription record by Part 4 of Schedule 1 to the rules in force under subsection 99AAA(8) of the Act, as modified by paragraph 29 of these Arrangements.
-
Subject to paragraph 27, a claim by the approved hospital authority in respect of chemotherapy pharmaceuticals supplied to the patients of the hospital may be furnished unaccompanied by the medication charts in respect of which chemotherapy pharmaceuticals have been supplied to the patients of the hospital.
-
If the Medicare Australia CEO notifies the approved hospital authority that a copy of all or any of the medication charts in respect of chemotherapy pharmaceuticals supplied to the patients of the hospital is required to be submitted, the approved hospital authority must submit a copy of each such medication chart to the Medicare Australia CEO.
-
If the Medicare Australia CEO notifies the approved hospital authority that a copy of all or any of the electronic pharmacy records in respect of chemotherapy pharmaceuticals supplied to the patients of the hospital is required to be submitted, the approved hospital authority must submit a copy of each such electronic pharmacy record to the Medicare Australia CEO.
-
Information provided by electronic means to the Secretary by the approved hospital authority in respect of a claim in respect of chemotherapy pharmaceuticals supplied to the patients of the hospital will conform to the requirements of paragraph 5 of, and Schedule 1 to, the rules in force under subsection 99AAA(8) of the Act, provided that Part 4 of Schedule 1 to those rules is amended:
(a) by omitting the specifications for the field “Prescriber Number” and substituting “Seven bytes numeric, right justified, zero filled, being the prescriber number of the prescribing medical practitioner, issued by the Medicare Australia CEO, in pursuance of the function granted to him or her by subsection 18(a) of the Medicare Australia (Functions of Chief Executive Officer) Direction 2005 made under paragraph 5(1)(d) of the Medicare Australia Act 1973”; and
(b) by omitting the field “Filler” and substituting the following field:
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse"><tbody><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Aprepitant</span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="aIndent102"><span></span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy, when aprepitant is used in combination with a 5-hydroxytryptamine type</span><span> </span><span>3 receptor antagonist and dexamethasone, where treatment with aprepitant is limited to an initial dose of 125</span><span> </span><span>mg and 2 subsequent doses of 80</span><span> </span><span>mg per cycle of cytotoxic chemotherapy, and where the cytotoxic chemotherapy to be administered to the patient includes any of the following agents:</span></p><p class="tTable" style="margin-left:22.65pt"><span>altretamine;</span></p><p class="tTable" style="margin-left:22.65pt"><span>carmustine;</span></p><p class="tTable" style="margin-left:22.65pt"><span>cisplatin, when a single dose constitutes a cycle of chemotherapy;</span></p><p class="tTable" style="margin-left:22.65pt"><span>cyclophosphamide, at a dose of 1500</span><span> </span><span>mg per square metre per day or greater;</span></p><p class="tTable" style="margin-left:22.65pt"><span>dacarbazine;</span></p><p class="tTable" style="margin-left:22.65pt"><span>procarbazine, when a single dose constitutes a cycle of chemotherapy;</span></p><p class="tTable" style="margin-left:22.65pt"><span>streptozocin</span></p><p class="tTable" style="margin-left:11.3pt"><span>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer where cyclophosphamide and an anthracycline are to be</span><span> </span><span>co-administered, when aprepitant is used in combination with a 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone, and where treatment with aprepitant is limited to an intial dose of 125 mg and 2 subsequent doses of 80 mg per cycle of cytotoxic chemotherapy</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>"BCG Immunotherapeutic" (Bacillus Calmette-Guérin/Connaught strain)</span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Treatment of carcinoma in situ of the urinary bladder</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>"BCG-Tice" (Bacillus Calmette-Guérin/Tice strain)</span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Primary and relapsing superficial urothelial carcinoma of the bladder</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Bleomycin Sulfate</span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Germ cell neoplasms</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Lymphoma</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Calcium Folinate</span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>In respect of the tablet equivalent to 15 mg folinic acid:</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Antidote to folic acid antagonists</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>In respect of the injection equivalent to 50</span><span> </span><span>mg folinic acid in 5</span><span> </span><span>mL and injection equivalent to 100 mg folinic acid in 10 mL:</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>—</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Carboplatin</span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Cisplatin</span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Cladribine</span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Hairy cell leukaemia</span></p></td></tr><tr><td colspan="2" style="width:127.6pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable"><span>Cyclophosphamide</span></p></td><td style="width:306.15pt; padding-right:7.1pt; padding-left:7.1pt; vertical-align:top"><p class="tTable" style="margin-left:0pt; text-indent:0pt"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Cytarabine</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Docetaxel</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Advanced breast cancer after failure of prior therapy which includes an anthracycline</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="font-size:8pt"><span style="display:none"></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:11.3pt; text-indent:-5.65pt; font-size:8pt"><span>Locally advanced or metastatic non-small cell lung cancer</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Dolasetron Mesylate</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Doxorubicin Hydrochloride</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td rowspan="2" style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Doxorubicin Hydrochloride - Pegylated Liposomal</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Metastatic breast cancer, as monotherapy, after failure of prior therapy which includes capecitabine and a taxane</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Metastatic breast cancer, as monotherapy, where therapy with capecitabine or a taxane is contraindicated</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Epirubicin Hydrochloride</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Etoposide</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Etoposide Phosphate</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Fluorouracil</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Fotemustine</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Metastatic malignant melanoma</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Gemcitabine Hydrochloride</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Advanced breast cancer in combination with paclitaxel after failure of prior therapy which includes an anthracycline</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Advanced epithelial ovarian cancer, in combination with carboplatin, in patients who relapse more than 6 months after platinum-based therapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Locally advanced or metastatic non-small cell lung cancer</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Locally advanced or metastatic adenocarcinoma of the pancreas</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Locally advanced or metastatic bladder cancer, when used in combination with cisplatin</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Granisetron Hydrochloride</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Idarubicin Hydrochloride</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Acute myelogenous leukaemia</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Ifosfamide</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Relapsed or refractory germ cell tumours following first-line chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Relapsed or refractory sarcomas following first-line chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Interferon Alfa-2a</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In respect of the injection 3,000,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:16.95pt"><span>Hairy cell leukaemia</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:16.95pt"><span>Myeloproliferative disease with excessive thrombocytosis</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:16.95pt"><span>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In respect of the injection 4,500,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe, injection 6,000,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe and injection 9,000,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:16.95pt"><span>Myeloproliferative disease with excessive thrombocytosis</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:16.95pt"><span>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Interferon Alfa-2b</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In respect of the solution for injection 18,000,000</span><span> </span><span>I.U. in 1.2</span><span> </span><span>mL multi-dose injection pen:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:16.95pt"><span>Hairy cell leukaemia</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:16.95pt"><span>Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:16.95pt"><span>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In respect of the solution for injection 30,000,000</span><span> </span><span>I.U. in 1.2</span><span> </span><span>mL multi-dose injection pen:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:16.95pt"><span>Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:16.95pt"><span>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Irinotecan Hydrochloride Trihydrate</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Metastatic colorectal cancer in patients with a World Health Organisation performance status of 2 or less</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Mesna</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Methotrexate</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Mitozantrone Hydrochloride</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Ondansetron</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Ondansetron Hydrochloride Dihydrate</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Oxaliplatin</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Metastatic colorectal cancer in patients with a World Health Organisation performance status of 2 or less, when used in combination with fluorouracil sodium and calcium folinate</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Adjuvant treatment of stage III (Dukes C) colon cancer, in combination with fluorouracil sodium and calcium folinate, following complete resection of the primary tumour</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Paclitaxel</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Adjuvant treatment of node-positive, oestrogen receptor negative, breast cancer administered sequentially to doxorubicin hydrochloride and cyclophosphamide</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Advanced breast cancer after failure of prior therapy which includes an anthracycline</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Primary treatment of ovarian cancer in combination with a platinum compound</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Locally advanced or metastatic non-small cell lung cancer</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Pemetrexed Disodium Heptahydrate</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:11.3pt; text-indent:-5.65pt; font-size:8pt"><span>Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:11.3pt; text-indent:-5.65pt; font-size:8pt"><span>Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where treatment with paclitaxel or docetaxel is contraindicated</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:11.3pt; text-indent:-5.65pt; font-size:8pt"><span>Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where intolerance to treatment with either docetaxel or paclitaxel has developed</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:11.3pt; text-indent:-5.65pt; font-size:8pt"><span>Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where treatment with either docetaxel or paclitaxel has been unsuccessful</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:11.3pt; text-indent:-5.65pt; font-size:8pt"><span>Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where transfer to docetaxel or paclitaxel is likely to result in adverse clinical consequences</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Raltitrexed</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>For use as a single agent in the treatment of advanced colorectal cancer</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Rituximab</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Relapsed or refractory follicular B-cell non-Hodgkin's lymphoma</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Treatment of symptomatic patients with previously untreated, CD20 positive, Stage III or IV, follicular, B-cell non-Hodgkin's lymphoma, in combination with chemotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Temozolomide</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In respect of the capsule 5 mg, capsule 20 mg and capsule 100 mg:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="text-indent:3.1pt"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt; text-indent:4.55pt"><span>Glioblastoma multiforme concomitantly with radiotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt; text-indent:4.55pt"><span>Recurrence of anaplastic astrocytoma following standard therapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt; text-indent:4.55pt"><span>Recurrence of glioblastoma multiforme following standard therapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt; text-indent:4.55pt"><span>Glioblastoma multiforme following radiotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In respect of the capsule 250 mg:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="text-indent:3.1pt"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt; text-indent:4.55pt"><span>Recurrence of anaplastic astrocytoma following standard therapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt; text-indent:4.55pt"><span>Recurrence of glioblastoma multiforme following standard therapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt; text-indent:4.55pt"><span>Glioblastoma multiforme following radiotherapy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Thiotepa</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Topotecan Hydrochloride</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Tropisetron Hydrochloride</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Vinblastine Sulfate</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Vincristine Sulfate</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>—</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>Vinorelbine Tartrate</span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Advanced breast cancer after failure of prior therapy which includes an anthracycline</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:309.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Locally advanced or metastatic non-small cell lung cancer</span></p></td></tr><tr><td style="vertical-align:top"></td><td style="width:129.3pt; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="font-size:8pt"><span></span></p></td><td style="width:309.55pt; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="font-size:8pt"><span></span></p></td></tr><tr style="height:0pt"><td style="width:1.7pt"></td><td style="width:140.1pt"></td><td style="width:320.35pt"></td></tr></tbody></table> ``` <table cellspacing="0" cellpadding="0" style="border-collapse:collapse"><tbody><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Epirubicin Hydrochloride</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for injection 10</span><span> </span><span>mg in 5</span><span> </span><span>mL</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection or intravesical administration</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>4</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>IT, PH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for injection 20</span><span> </span><span>mg in 10</span><span> </span><span>mL</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection or intravesical administration</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>4</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span><span>PH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for injection 50</span><span> </span><span>mg in 25</span><span> </span><span>mL</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection or intravesical administration</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>3</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>IT, PH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for injection 50 mg</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection or intravesical administration</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>3</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for injection 100 mg in 50 mL</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection or intravesical administration</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>IT</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for injection 200 mg in 100 mL</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection or intravesical administration</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>IT</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Etoposide</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for I.V. infusion 100</span><span> </span><span>mg in 5</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>IT, MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Etoposide Phosphate</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for I.V. infusion 113.6</span><span> </span><span>mg, vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BQ</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for I.V. infusion 1.136</span><span> </span><span>g, vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BQ</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Fluorouracil</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection 500</span><span> </span><span>mg in 10</span><span> </span><span>mL</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>10</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>IT, MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection 1000</span><span> </span><span>mg in 20</span><span> </span><span>mL</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>IT</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Fotemustine</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for injection 208 mg with solvent</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>4</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>SE</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Gemcitabine Hydrochloride</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for I.V. infusion equivalent to 200</span><span> </span><span>mg gemcitabine</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>4</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>LY</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for I.V. infusion equivalent to 1</span><span> </span><span>g gemcitabine</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>LY</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Granisetron Hydrochloride</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Tablet equivalent to 2 mg granisetron</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Concentrated injection equivalent to 3 mg granisetron in 3 mL ampoule</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Idarubicin Hydrochloride</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Capsule 5</span><span> </span><span>mg</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>3</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>PH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Capsule 10</span><span> </span><span>mg</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>3</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>PH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for I.V. injection 5</span><span> </span><span>mg in 5</span><span> </span><span>mL single use vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>3</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>PH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for I.V. injection 10</span><span> </span><span>mg in 10</span><span> </span><span>mL single use vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>6</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>PH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Ifosfamide</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for I.V. injection 1</span><span> </span><span>g in single dose vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>5</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for I.V. injection 2</span><span> </span><span>g in single dose vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>5</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Interferon Alfa-2a</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection 3,000,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>15</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>4</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>RO</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection 4,500,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>4</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>RO</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection 6,000,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>4</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>RO</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection 9,000,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>4</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>RO</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Interferon Alfa-2b</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for injection 18,000,000</span><span> </span><span>I.U. in 1.2</span><span> </span><span>mL multi-dose injection pen</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>3</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>4</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>SH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for injection 30,000,000</span><span> </span><span>I.U. in 1.2</span><span> </span><span>mL multi-dose injection pen</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>3</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>5</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>SH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Irinotecan Hydrochloride Trihydrate</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>I.V. injection 40</span><span> </span><span>mg in 2</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>3</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>MX, PU</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>I.V. injection 100</span><span> </span><span>mg in 5</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>3</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>MX, PU</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Mesna</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for I.V. injection 400</span><span> </span><span>mg in 4</span><span> </span><span>mL ampoule</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>15</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>5</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for I.V. injection 1</span><span> </span><span>g in 10</span><span> </span><span>mL ampoule</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>15</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>5</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Methotrexate</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection 5</span><span> </span><span>mg in 2</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection 50</span><span> </span><span>mg in 2</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>MX, PU</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution concentrate for I.V. infusion</span><span> </span><span>500 mg in 5 mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>IT</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution concentrate for I.V. infusion</span><span> </span><span>500 mg in 20 mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution concentrate for I.V. infusion</span><span> </span><span>1000 mg in 10 mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>IT, MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution concentrate for I.V. infusion</span><span> </span><span>5000 mg in 50 mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>IT</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Mitozantrone Hydrochloride</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection equivalent to 10</span><span> </span><span>mg mitozantrone in 5</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>PU</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection equivalent to 20</span><span> </span><span>mg mitozantrone in 10</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BX, MX, PU, SI</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection equivalent to 25</span><span> </span><span>mg mitozantrone in 12.5</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BX, PU, SI</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Ondansetron</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Wafer 4</span><span> </span><span>mg</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>4</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>GK, HX, RE</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Wafer 8</span><span> </span><span>mg</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>4</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>GK, HX, RE</span></p></td></tr><tr><td rowspan="2" style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Ondansetron Hydrochloride Dihydrate</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Tablet equivalent to 4</span><span> </span><span>mg ondansetron</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>4</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>AW, GK, HX, RE</span></p></td></tr><tr><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Tablet equivalent to 8</span><span> </span><span>mg ondansetron</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>4</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>AW, GK, HX, RE</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>I.V. injection equivalent to 4</span><span> </span><span>mg ondansetron in 2</span><span> </span><span>mL ampoule</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>GK, HX, RE</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>I.V. injection equivalent to 8</span><span> </span><span>mg ondansetron in 4</span><span> </span><span>mL ampoule</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>GK, HX, RE</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oxaliplatin</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution concentrate for I.V. infusion</span><span> </span><span>50 mg in 10 mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>SW</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution concentrate for I.V. infusion</span><span> </span><span>100 mg in 20 mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>SW</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Paclitaxel</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution concentrate for I.V. infusion 30</span><span> </span><span>mg in 5</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BQ, IT, MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution concentrate for I.V. infusion 100</span><span> </span><span>mg in 16.7</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BQ, IT, MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution concentrate for I.V. infusion 150</span><span> </span><span>mg in 25</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BQ, IT, MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution concentrate for I.V. infusion 300</span><span> </span><span>mg in 50</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>BQ, IT, MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Pemetrexed Disodium Heptahydrate</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for I.V. infusion equivalent to 500</span><span> </span><span>mg pemetrexed, vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>LY</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Raltitrexed</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for I.V. infusion 2</span><span> </span><span>mg in single use vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>3</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>AP</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Rituximab</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for I.V. infusion 100</span><span> </span><span>mg in 10</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>3</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>RO</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for I.V. infusion 500</span><span> </span><span>mg in 50</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>3</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>RO</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Temozolomide</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Capsule 5</span><span> </span><span>mg</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>15</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>SH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Capsule 20</span><span> </span><span>mg</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>15</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>SH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Capsule 100</span><span> </span><span>mg</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>15</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>SH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Capsule 250</span><span> </span><span>mg</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>5</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>SH</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Thiotepa</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for injection 15</span><span> </span><span>mg</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection or intravesical administration</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>1</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>SI</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Topotecan Hydrochloride</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Powder for I.V. infusion equivalent to 4</span><span> </span><span>mg topotecan, vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>1</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>GK</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Tropisetron Hydrochloride</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Capsule equivalent to 5</span><span> </span><span>mg tropisetron</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Oral</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>NV</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>I.V. injection equivalent to 5</span><span> </span><span>mg tropisetron in 5</span><span> </span><span>mL ampoule</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>1</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>NV</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Vinblastine Sulfate</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for I.V. injection 10</span><span> </span><span>mg in 10</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>5</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Vincristine Sulfate</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>I.V. injection 1</span><span> </span><span>mg in 1</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>10</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>..</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>MX, PU</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span></span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span></span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Vinorelbine Tartrate</span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for I.V. infusion equivalent to 10</span><span> </span><span>mg vinorelbine in 1</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>16</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>FB, IT, MX</span></p></td></tr><tr><td style="width:122pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:136.15pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Solution for I.V. infusion equivalent to 50</span><span> </span><span>mg vinorelbine in 5</span><span> </span><span>mL vial</span></p></td><td style="width:53.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>4</span></p></td><td style="width:36.95pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:34.2pt; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p class="tTable"><span>FB, IT, MX</span></p></td></tr><tr><td style="width:122pt; border-bottom:0.75pt solid #000000; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p style="font-size:8pt"><span></span></p></td><td style="width:136.15pt; border-bottom:0.75pt solid #000000; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p style="font-size:8pt"><span></span></p></td><td style="width:53.95pt; border-bottom:0.75pt solid #000000; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p style="font-size:8pt"><span></span></p></td><td style="width:36.95pt; border-bottom:0.75pt solid #000000; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p style="text-align:center; font-size:8pt"><span></span></p></td><td style="width:36.95pt; border-bottom:0.75pt solid #000000; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p style="font-size:8pt"><span></span></p></td><td style="width:34.2pt; border-bottom:0.75pt solid #000000; padding-right:2.8pt; padding-left:2.8pt; vertical-align:top"><p style="font-size:8pt"><span></span></p></td></tr></tbody></table> ``` <table cellspacing="0" cellpadding="0" style="border-collapse:collapse"><tbody><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Interferon</span><span> </span><span>Alfa-2a</span></p></td><td rowspan="2" style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Injection 3,000,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe</span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span>15</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span>5</span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>RO</span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td rowspan="2" style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Injection 4,500,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe</span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span>5</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span>5</span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>RO</span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td rowspan="2" style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Injection 6,000,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe</span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span>5</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span>5</span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>RO</span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td rowspan="2" style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Injection 9,000,000</span><span> </span><span>I.U. in 0.5</span><span> </span><span>mL single dose pre-filled syringe</span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span>5</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span>5</span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>RO</span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Interferon</span><span> </span><span>Alfa-2b</span></p></td><td rowspan="2" style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Solution for injection 18,000,000</span><span> </span><span>I.U. in 1.2</span><span> </span><span>mL multi-dose injection pen</span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span>3</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span>5</span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>SH</span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="margin-left:11.3pt"><span>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable" style="text-align:center"><span></span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Pemetrexed Disodium Heptahydrate</span></p></td><td style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Powder for I.V. infusion equivalent to 500 mg pemetrexed, vial</span></p></td><td rowspan="2" style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>In compliance with authority procedures set out in paragraph 14:</span></p><p style="margin-left:11.3pt; text-indent:-5.65pt; font-size:8pt"><span>Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where treatment with paclitaxel or docetaxel is contraindicated</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>Injection</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span>2</span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTableC"><span>2</span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span>LY</span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTableC"><span></span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p style="margin-left:11.3pt; text-indent:-5.65pt; font-size:8pt"><span>Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where intolerance to treatment with either docetaxel or paclitaxel has developed</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTableC"><span></span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p style="margin-left:11.3pt; text-indent:-5.65pt; font-size:8pt"><span>Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where treatment with either docetaxel or paclitaxel has been unsuccessful</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTableC"><span></span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr><tr><td style="width:51.05pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:82.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:133.3pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p style="margin-left:11.3pt; text-indent:-5.65pt; font-size:8pt"><span>Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where transfer to docetaxel or paclitaxel is likely to result in adverse clinical consequences</span></p></td><td style="width:38.25pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTableR" style="text-align:center"><span></span></p></td><td style="width:42.55pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTableC"><span></span></p></td><td style="width:36.9pt; padding-right:1.4pt; padding-left:1.4pt; vertical-align:top"><p class="tTable"><span></span></p></td></tr></tbody></table> ```